<?xml-stylesheet type='text/xsl' href='ctgovTransform.xsl'?>
<CT.GOV_Trial requestNumber="3823">
  <stage>Registered</stage>
  <submitdate>30/04/2012</submitdate>
  <approvaldate>30/04/2012</approvaldate>
  <nctid>NCT01589822</nctid>
  <trial_identification>
    <studytitle>The EVICEL® Gastrointestinal Study</studytitle>
    <scientifictitle>A Single Blind, Randomized, Controlled Study to Evaluate the Safety and Effectiveness of EVICEL® as an Adjunct to Gastrointestinal Anastomosis Techniques</scientifictitle>
    <utrn />
    <trialacronym />
    <secondaryid>400-11-002</secondaryid>
  </trial_identification>
  <conditions>
    <healthcondition>Gastrointestinal Diseases</healthcondition>
  </conditions>
  <interventions>
    <interventions>Other interventions - EVICEL Fibrin Sealant

Experimental: EVICEL Fibrin Sealant: Randomized - EVICEL is a human plasma-derived fibrin sealant composed of two components - thrombin and fibrinogen.

No Intervention: Standard of Care - Standard surgical technique for GI anastomosis.

Experimental: Experimental: EVICEL Fibrin Sealant: Non-Randomized - EVICEL is a human plasma-derived fibrin sealant composed of two components - thrombin and fibrinogen


Other interventions: EVICEL Fibrin Sealant
Intraoperative

</interventions>
    <comparator />
    <control />
    <interventioncode>Other interventions interventions</interventioncode>
  </interventions>
  <outcomes>
    <primaryOutcome>
      <outcome>Absence of Gastrointestinal (GI) Leak</outcome>
      <timepoint>40 days</timepoint>
    </primaryOutcome>
    <secondaryOutcome>
      <outcome>Incidence of Adverse Events</outcome>
      <timepoint>up to Day 90</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Incidence of GI Leak</outcome>
      <timepoint>90 days</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Incidence of Stricture</outcome>
      <timepoint>up to Day 90</timepoint>
    </secondaryOutcome>
  </outcomes>
  <eligibility>
    <inclusivecriteria>-  Subjects undergoing primary elective GI surgery

          -  Subjects = 18 years of age who are willing to participate in the study and provide
             written informed consent prior to any study-related procedures</inclusivecriteria>
    <inclusiveminage>18</inclusiveminage>
    <inclusiveminagetype>Years</inclusiveminagetype>
    <inclusivemaxage />
    <inclusivemaxagetype>No limit</inclusivemaxagetype>
    <inclusivegender>Both males and females</inclusivegender>
    <healthyvolunteer>No</healthyvolunteer>
    <exclusivecriteria>-  Avastin use within 30 days prior to surgery;

          -  Known hypersensitivity to the human blood products or the components of the
             investigational product;

          -  Female subjects who are pregnant or nursing;

          -  Exposure to another investigational drug or device in a clinical trial within 30 days
             prior to surgery or planned/intended for the 90 day follow up period after surgery.</exclusivecriteria>
  </eligibility>
  <trial_design>
    <studytype>Interventional</studytype>
    <purpose>Treatment</purpose>
    <allocation>Randomised controlled trial</allocation>
    <concealment />
    <sequence />
    <masking>Blinded (masking used)</masking>
    <assignment>Parallel</assignment>
    <designfeatures />
    <endpoint />
    <statisticalmethods />
    <masking1>The people receiving the treatment/s</masking1>
    <masking2 />
    <masking3 />
    <masking4 />
    <patientregistry />
    <followup />
    <followuptype />
    <purposeobs />
    <duration />
    <selection />
    <timing />
  </trial_design>
  <recruitment>
    <phase>Phase 2</phase>
    <anticipatedstartdate />
    <actualstartdate>1/06/2012</actualstartdate>
    <anticipatedenddate />
    <actualenddate />
    <samplesize />
    <actualsamplesize>214</actualsamplesize>
    <recruitmentstatus>Completed</recruitmentstatus>
    <anticipatedlastvisitdate />
    <actuallastvisitdate>1/09/2014</actuallastvisitdate>
    <dataanalysis />
    <withdrawnreason />
    <withdrawnreasonother />
    <recruitmentcountry>Australia</recruitmentcountry>
    <recruitmentstate>NSW</recruitmentstate>
    <hospital>Clinical Investigation Site #19 - New Lambton</hospital>
    <hospital>Clinical Investigation Site #18 - South Adelaide</hospital>
    <postcode>2305 - New Lambton</postcode>
    <postcode>6010 - South Adelaide</postcode>
    <countryoutsideaustralia>
      <country>United States</country>
      <state>California</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United States</country>
      <state>Florida</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United States</country>
      <state>Georgia</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United States</country>
      <state>Louisiana</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United States</country>
      <state>Oregon</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United States</country>
      <state>South Carolina</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United States</country>
      <state>Texas</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Belgium</country>
      <state>Genk</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Belgium</country>
      <state>Ghent</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Canada</country>
      <state>British Columbia</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Canada</country>
      <state>Ontario</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Korea, Republic of</country>
      <state>Seoul</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>New Zealand</country>
      <state>Auckland</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United Kingdom</country>
      <state>Edinburgh</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United Kingdom</country>
      <state>Leicester</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United Kingdom</country>
      <state>Nottingham</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United Kingdom</country>
      <state>Plymouth</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United Kingdom</country>
      <state>Sheffield</state>
    </countryoutsideaustralia>
  </recruitment>
  <sponsorship>
    <primarysponsortype>Commercial sector/Commercial sector/Industry</primarysponsortype>
    <primarysponsorname>Ethicon, Inc.</primarysponsorname>
    <primarysponsoraddress />
    <primarysponsorcountry />
  </sponsorship>
  <ethicsAndSummary>
    <summary>The purpose of this study is to evaluate the safety and effectiveness of EVICEL® Fibrin
      Sealant (Human) for use as an adjunct to gastrointestinal (GI) surgery.</summary>
    <trialwebsite>https://clinicaltrials.gov/show/NCT01589822</trialwebsite>
    <publication />
    <ethicsreview />
    <publicnotes />
  </ethicsAndSummary>
  <attachment />
  <contacts>
    <contact>
      <title />
      <name>Richard Kocharian, MD</name>
      <address>Ethicon, Inc.</address>
      <phone />
      <fax />
      <email />
      <country />
      <type>Principal Investigator</type>
    </contact>
    <contact>
      <title />
      <name />
      <address />
      <phone />
      <fax />
      <email />
      <country />
      <type>Public Queries</type>
    </contact>
  </contacts>
</CT.GOV_Trial>